DDInter1717 DDInter1259
Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances [A177655, F4519]. Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076].
Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Sucralfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norfloxacin
Norfloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Sucralfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomefloxacin
Lomefloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Sucralfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norfloxacin
Norfloxacin {u} (Compound) resembles {v} (Compound) Rosoxacin
Rosoxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Sucralfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomefloxacin
Lomefloxacin {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Sucralfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Sucralfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomefloxacin
Lomefloxacin {u} (Compound) resembles {v} (Compound) Pefloxacin
Pefloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Sucralfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Sucralfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Lomefloxacin
Lomefloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Sucralfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomefloxacin
Lomefloxacin {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Erythema multiforme {u} (Side Effect) is caused by {v} (Compound) Nalidixic acid
Sucralfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norfloxacin
Norfloxacin {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Nalidixic acid
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin (Compound) resembles Nalidixic acid (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Nalidixic acid (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin (Compound) resembles Rosoxacin (Compound) and Rosoxacin (Compound) resembles Nalidixic acid (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin (Compound) resembles Nalidixic acid (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin (Compound) resembles Nalidixic acid (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Pefloxacin (Compound) and Pefloxacin (Compound) resembles Nalidixic acid (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin (Compound) resembles Nalidixic acid (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin (Compound) resembles Nalidixic acid (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Nalidixic acid (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Nalidixic acid (Compound)